Home » Blog » Value-Based Care, Quality Payment Program, Research Funding, Telomeres, and the ROCKET Trial

Value-Based Care, Quality Payment Program, Research Funding, Telomeres, and the ROCKET Trial


IP Blog | Dave Melin | November 27, 2016

BioBlog Weekly oncologyThis week’s BioBlog focuses on the the continued push toward Value-Based Care even with expected changes to the ACA, physician readiness to comply with the Quality Payment Program, cancer research funding, telomere research, and cancer treatment trial complications.

End of ACA Won’t Stop March Toward Value-Based Care, Experts Say

PRWeb reports that they expect Trump to eliminate the Affordable Care Act via a budget reconciliation early in his term, while still keeping some elements of it including the trend toward value-based care.

How ASCO Is Preparing Members for MACRA

In this article, The ASCO Post discusses the implementation of the Quality Payment Program and what adjustments physicians need to make to meet the new requirements of this program.

Revolutionary Advances in Microscopy Provide an Opportunity to Break a Roadblock in Cancer Research

The University of Queensland in Australia was awarded a $2.3 million grant to study and track how cancer cells grow and react to various cancer treatments.

To Disrupt Cancer Growth, 2 Pittsburgh Labs Try Cutting its Fuel

Two University of Pittsburgh Medical Center labs are currently researching telomeres and the role they play in the spread of cancer.

Cancer Immunotherapy Trial Stopped Again After 2 More Deaths

CNN Reports that the ROCKET immunotherapy trial has been halted again after two more participants experienced cerebral edema and passed away. Earlier this year the trial was temporarily stopped when three additional participants died.


Topics in this Post:



Leave a Comment

Your email address will not be published. Required fields are marked *